PARP1 inhibitors combined with ADCs and their use in cancer treatment

TW202637155APending Publication Date: 2026-09-16KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115102822
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-01-23
Filing Date
2026-01-23
Publication Date
2026-09-16

Smart Images

  • Figure TWG2TA001077102_001
    Figure TWG2TA001077102_001
  • Figure TWG2TA001077102_002
    Figure TWG2TA001077102_002
Patent Text Reader

Abstract

This invention relates to a combination of PARP1 inhibitors and ADCs and their use in the treatment of tumors. The antitumor efficacy and safety of PARP1 inhibitors combined with ADCs are significantly better than those of ADCs alone, and they have a significant synergistic effect.
Need to check novelty before this filing date? Find Prior Art